National Tunisian Registry of Heart Failure
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 2,040
- 试验地点
- 1
- 主要终点
- Cardiovascular death
研究概览
简要总结
NATURE-HF is an observational, multicentric and longitudinal study of heart failure performed with 100 tunisian cardiologists.
详细描述
The NATURE-HF is a national clinical non-interventional registry of heart failure, carried out in Tunisia at cardiology departments in hospitals and in liberal cardiology consultations. 100 cardiologists participate in the enrollment of the eligible patients as investigators. A Committee of Experts validates the protocol methodology and supervises the data-management. A Steering Committee helps investigators to monitor their patient inclusions, performs audit trails and prepares the statistical analysis plan for the study.
Collected data are managed by the DACIMA Clinical Suite®, the electronic data capture platform which complies with the FDA 21 CFR part 11 requirements (Food and Drug Administration 21 Code of Federal Regulations part 11), the HIPAA specifications (Health Insurance Portability and Accountability Act), and the ICH standards (International Conference on Harmonisation).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 20 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient with chronic heart failure
- •Patient with acute heart failure (new onset or not)
- •The diagnosis of heart failure is at the discretion of the investigator
- •Informed and signed consent
排除标准
- •Life expectancy <12 months for extra cardiac disease
- •Isolated Right Heart Failure
- •Pregnant woman
- •Renal failure with creatinine clearance < 15 ml / min
- •Hemodialysis patients
- •Cardiac surgery planned within 3 months
- •Congenital heart disease
结局指标
主要结局
Cardiovascular death
时间窗: Time-To-Event measure up to 12 months from baseline
Incidence of cardiovascular death including sudden death, death from refractory heart failure and death from stroke
次要结局
- Global Death(Time-To-Event measure up to 12 months from baseline)
- Heart Failure Readmission(At 1, 3 and 12 months from patient enrollment)
